SEC filing · 10-K

Neuphoria Therapeutics Inc.: Annual report

Neuphoria restructured operations and agreed to be acquired by Scancell after its lead drug candidate failed a Phase 3 clinical trial.

Filed September 18, 2026 · period ended June 30, 2026

Negative for the company

What the numbers say

Revenue fell 92% to $1.2M versus the prior year; operating margin narrowed from -7.2% to -1,401.1%; diluted EPS -$3.06 versus -$0.23; operating cash flow -$12.4M (a year earlier $77.2K); cash rose by $5.7M to $19.9M; diluted share count up 171% (dilution).

Compared with the same period a year earlier, from the figures Neuphoria Therapeutics Inc. reported to the SEC.

What happened

The Phase 3 AFFIRM-1 trial of BNC210 in social anxiety disorder did not meet its primary endpoint, leading Neuphoria to discontinue the program.

The full interpretation is in the app

Why it matters, the key numbers from the document and what to watch next: the full interpretation of every report is part of Pro.

Read the full interpretation

Read the original

Filing document on SEC.gov All documents of this filing

Back to Neuphoria Therapeutics Inc.

Summary generated automatically from the filing text and checked against it: every number above is printed in the document. It describes the filing and is not investment advice. Read the original before relying on it.